Last reviewed · How we verify
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Interventional Study of JNJ-61178104 in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity of JNJ-61178104 following a single ascending Intravenous (IV) dose administration and a single Subcutaneous (SC) dose administration in healthy participants.
Details
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 54 |
| Start date | 2016-04 |
| Completion | 2017-01 |
Conditions
- Healthy
Interventions
- JNJ-61178104 Intravenous
- JNJ-61178104 Subcutaneous
- Placebo
Primary outcomes
- Number of Participants With Adverse Events Following Study Drug Administration as a Measure of Safety and Tolerability — Day 113
Countries
Belgium